文献速递临床试验与 GCP流行病学与生物统计

可切除非小细胞肺癌纵隔分期:联合或不联合外科纵隔镜检查的MEDIASTrial统计分析计划

MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): a statistical analysis plan.
PubMed 文献 · Trials · 2021-02-27

MEDIASTrial是一项非劣效性试验,评估在可切除NSCLC患者中,超声内镜纵隔分期阴性后省略确认性纵隔镜检查是否安全。主要终点为肺叶特异性纵隔淋巴结清扫发现意外N2病变率,其95%CI上限需不超过14.3%。本文为试验关闭前公开的统计分析计划,涵盖ITT和PP分析及次要终点。

要点

  • 指南推荐可切除NSCLC选择性患者行有创纵隔分期,超声内镜为首选,阴性后是否需确认性纵隔镜存在争议。
  • MEDIASTrial主要终点为意外N2率,非劣效界值为95%CI上限不超过14.3%。
  • ITT和PP分析均需显示非劣效,才能判定省略纵隔镜的策略非劣于联合策略。

核心结论

  • MEDIASTrial将确定在肿瘤阴性系统性超声内镜后,可切除NSCLC患者的有创纵隔分期中能否省略确认性纵隔镜检查。

研究设计与样本

  • 非劣效性试验,比较超声内镜后省略与不省略确认性纵隔镜的纵隔分期策略。
  • 主要分析同时采用意向性分析(ITT)和符合方案分析(PP)。
  • 试验注册于荷兰试验注册库NL6344/NTR6528,注册日期2017年7月6日。

主要发现

  • 本文为统计分析计划,未报告试验结果。

关键数值与推荐

  • 主要终点为肺叶特异性纵隔淋巴结清扫发现的意外N2病变率。
  • 非劣效界值:省略纵隔镜组意外N2率的95%置信区间上限不得超过14.3%。
  • ITT和PP分析均需显示非劣效,才可判定省略纵隔镜策略非劣于联合策略。
  • 次要终点包括30天主要并发症和死亡率、总住院天数、2年总生存和无病生存、健康相关生活质量及成本效果和成本效用。

临床怎么用

  • 若结果支持非劣效,可切除NSCLC患者超声内镜纵隔分期阴性后可安全省略确认性纵隔镜检查。

局限性

  • 原文未报告试验结果,无法评估省略纵隔镜策略的实际非劣效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive mediastinal nodal staging is recommended by guidelines in selected patients with resectable non-small cell lung cancer (NSCLC). Endosonography is recommended as initial staging technique, followed by confirmatory mediastinoscopy in case of negative N2 or N3 cytology after endosonography. Confirmatory mediastinoscopy however is under debate owing its limited additional diagnostic value, its associated morbidity and its delay in the start of lung cancer treatment. The MEDIASTrial examines whether confirmatory mediastinoscopy can be safely omitted after negative endosonography in mediastinal nodal staging of NSCLC. The present work is the proposed statistical analysis plan of the clinical consequences of omitting mediastinoscopy, which is submitted before closure of the MEDIASTrial and before knowledge of any results was done to enhance transparency of scientific behaviour. METHODS: The primary outcome measure of this non-inferiority trial will be unforeseen N2 disease resulting from lobe-specific mediastinal lymph node dissection. For non-inferiority, the upper limit of the 95% confidence interval of the unforeseen N2 rate in the group without mediastinoscopy should not exceed 14.3% in order to probably have no negative impact on survival. Since this is a non-inferiority trial, both an intention to treat (ITT) and a per protocol (PP) analyses will be done. The ITT and the PP analyses should both indicate non-inferiority before the diagnostic strategy omitting mediastinoscopy will be interpreted as non-inferior to the strategy with mediastinoscopy. Secondary outcome measures include 30-day major morbidity and mortality, the total number of days of hospital care, overall and disease free 2-year survival, generic and disease-specific health related quality of life and cost-effectiveness and cost-utility of staging strategies with and without mediastinoscopy. DISCUSSION: The MEDIASTrial will determine if confirmatory mediastinoscopy can be omitted after tumour negative systematic endosonography in invasive mediastinal staging of patients with resectable NSCLC. TRIAL REGISTRATION: Netherlands Trial Register NL6344/NTR6528 . Registered on 2017 July 06.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bousema JE, Annema JT, van der Heijden EHFM, et al. MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): a statistical analysis plan. Trials. 2021. PMID: 33639999. doi:10.1186/s13063-021-05127-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。